Skip to main content
. 2023 Jun 20;26(6):407–415. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2023.102.18

表4.

PD-L1≥50%晚期转移性疾病的免疫治疗方案

Pathological
subtype 		First-line therapy Continuation maintenance
Preferred Other recommended
Adenocarcinoma, large cell, NSCLC not otherwise specified Pembrolizumab (category 1);
Carboplatin or Cisplatin+
Pemetrexed+Pembrolizumab (category 1);
Atezolizumab (category 1);
Cemiplimab-rwlc (category 1)		 Carboplatin+Paclitaxel+ Bevacizumab+Atezolizumab (category 1);
Carboplatin+albumin-bound Paclitaxel+Atezolizumab;
Nivolumab+Ipilimumab+Pemetrexed+
Carboplatin or Cisplatin (category 1);
Cemiplimab-rwlc+Paclitaxel+Carboplatin or Cisplatin (category 1);
Cemiplimab-rwlc+Pemetrexed+Carboplatin or Cisplatin (category 1);
Tremelimumab-actl+Durvalumab+Carboplatin+albumin-bound Paclitaxel (category 2B);
Tremelimumab-actl+Durvalumab+Carboplatin or Cisplatin+Pemetrexed (category 2B)		 Pembrolizumab (category 1);
Pembrolizumab+Pemetrexed (category 1);
Atezolizumab+Bevacizumab (category 1);
Atezolizumab;
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc (category 1); Cemiplimab-rwlc±Pemetrexed (category 1);
Durvalumab±Pemetrexed
Squamous cell carcinoma Pembrolizumab (category 1);
Carboplatin+Paclitaxel or albumin-bound Paclitaxel+ Pembrolizumab (category 1);
Atezolizumab (category 1);
Cemiplimab-rwlc (category 1)		 Nivolumab+Ipilimumab+Paclitaxel+Carboplatin (category 1);
Cemiplimab-rwlc+Paclitaxel+Carboplatin or Cisplatin (category 1);
Tremelimumab-actl+
Durvalumab+Carboplatin+albumin-bound Paclitaxel (category 2B);
Tremelimumab-actl+Durvalumab+Carboplatin or Cisplatin+Gemcitabine (category 2B)		 Pembrolizumab (category 1);
Atezolizumab;
Nivolumab+Ipilimumab (category 1);
Cemiplimab-rwlc (category 1); Durvalumab